Top Abstract Purchase Related
Home
>
Node
>
Subnode

Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin

Pindur, G.; Köhler, M.; Heiden, M.; Leipnitz, C.; Rupp, K.H.; Wenzel, E.

Langenbecks Archiv für Chirurgie. Supplement Ii Verhandlungen der Deutschen Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress 1990: 1149-1155

1990

ISSN/ISBN: 0173-0541
PMID: 1983502
Document Number: 355842
Heparin exerts its anticoagulant function by accelerating the inhibitory effect of antithrombin III. Low molecular weight heparin (LMWH), which is derived from unfractionated heparin (UFH), exhibits marked anti-Xa activity and minor thrombin inhibition. It has an elevated bioavailability and longer half-life as to the anti-Xa clearance when compared to UFH. Platelet, endothelial and fibrinolytic effects are also involved in antithrombotic action. Clinical trials have shown that LMWH compared to UFH is an equivalent and even advantageous method of antithrombotic prophylaxis in surgical patients and has also a minor risk of bleeding.

Document emailed within 1 workday
Secure & encrypted payments

Broyer, M.; Gagnadoux, M.F.; Sierro, A.; Fischer, A.M.; Niaudet, P. 1991: Preventive treatment of vascular thrombosis after kidney transplantation in children with low molecular weight heparin Transplantation Proceedings 23(1 Pt 2): 1384-1385
Jeske, W.; Lojewski, B.; Walenga, J.M.; Hoppensteadt, D.; Ahsan, A.; Fareed, J. 1993: Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin) Seminars in Thrombosis and Hemostasis 19(Suppl 1): 229-240
Bergqvist, D. 1990: Low molecular weight heparin--preventive supplementation against postoperative venous thromboembolism Lakartidningen 87(8): 562-564
Levine, M.N.; Planes, A.; Hirsh, J.; Goodyear, M.; Vochelle, N.; Gent, M. 1989: The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement Thrombosis and Haemostasis 62(3): 940-944
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294
Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Neri Serneri, G.G. 1993: Heparin, low-molecular-weight heparin and their clinical use Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 8(2): 69-72
Barrowcliffe, T.W.; Le Shirley, Y. 1989: The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions Thrombosis and Haemostasis 62(3): 950-954
Osterkorn, D.; Schramm, W.; Szucs, T. 1996: Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home Medizinische Klinik 91(9): 607-609
Brieger, D.; Dawes, J. 1994: Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane) Thrombosis and Haemostasis 72(2): 275-280
Boccalon, H.; Elias, A.; Chalé, J.J.; Cadène, A.; Gabriel, S. 2000: Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study Archives of Internal Medicine 160(12): 1769-1773
Hassn, A.; Hassan, A.M. 1999: Treatment with low molecular weight heparin needs anticoagulation monitoring Journal of the American College of Surgeons 189(1): 141-142
Price, A.J.; Obeid, D. 1995: Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Annals of the Royal College of Surgeons of England 77(5): 395
Koppenhagen, K.; Tröster, E.; Matthes, M.; Häring, R. 1990: Prevention of thrombosis with low molecular weight heparin as the only substance and/or with DHE: results of clinical studies Langenbecks Archiv für Chirurgie. Supplement Ii Verhandlungen der Deutschen Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress 1990: 1163-1166
Jacobsen, A.F.; Qvigstad, E.; Sandset, P.M. 2000: Treatment of venous thromboembolism in pregnancy with low molecular weight heparin Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 120(20): 2448-2449
Paul, V.; Pudoor, A.; Earali, J.; John, B.; Anil Kumar, C.S.; Anthony, T. 2007: Trial of low molecular weight heparin in the treatment of viper bites Journal of the Association of Physicians of India 55: 338-342
Schwarz, B.; Mittelmeier, H. 1988: Initial clinical experiences with low molecular weight heparin in the prevention of thrombosis in orthopedic surgery Aktuelle Traumatologie 18(5): 226-232
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638